Nurix Therapeutics (NASDAQ:NRIX) Trading Down 3.2%

Nurix Therapeutics, Inc. (NASDAQ:NRIX) dropped 3.2% on Friday . The company traded as low as $23.66 and last traded at $23.66. Approximately 45,936 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 914,554 shares. The stock had previously closed at $24.44.

Analyst Upgrades and Downgrades

NRIX has been the topic of a number of research reports. Barclays raised their target price on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. Truist Financial initiated coverage on shares of Nurix Therapeutics in a research report on Wednesday, July 31st. They set a “buy” rating and a $36.00 price objective on the stock. Robert W. Baird started coverage on shares of Nurix Therapeutics in a report on Friday. They issued an “outperform” rating and a $26.00 target price for the company. JPMorgan Chase & Co. increased their target price on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Finally, Royal Bank of Canada boosted their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Friday, July 12th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.00.

Nurix Therapeutics Stock Down 5.7 %

The stock has a fifty day moving average of $22.11 and a two-hundred day moving average of $17.28. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -7.88 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.08). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The company had revenue of $12.09 million during the quarter, compared to analysts’ expectations of $19.35 million. On average, research analysts expect that Nurix Therapeutics, Inc. will post -2.95 EPS for the current year.

Insider Buying and Selling

In related news, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $51,468.30. Following the completion of the transaction, the chief financial officer now directly owns 54,479 shares of the company’s stock, valued at $1,126,080.93. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total transaction of $51,468.30. Following the completion of the transaction, the chief financial officer now owns 54,479 shares in the company, valued at $1,126,080.93. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Christine Ring sold 9,870 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $25.01, for a total transaction of $246,848.70. Following the transaction, the insider now directly owns 24,592 shares of the company’s stock, valued at $615,045.92. The disclosure for this sale can be found here. Insiders have sold a total of 61,715 shares of company stock worth $1,449,070 in the last quarter. Company insiders own 7.20% of the company’s stock.

Institutional Trading of Nurix Therapeutics

A number of large investors have recently made changes to their positions in NRIX. ProShare Advisors LLC raised its stake in Nurix Therapeutics by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after purchasing an additional 998 shares during the last quarter. ClariVest Asset Management LLC boosted its stake in Nurix Therapeutics by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $1,318,000 after buying an additional 1,766 shares during the last quarter. Public Employees Retirement System of Ohio grew its holdings in Nurix Therapeutics by 3.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock valued at $747,000 after buying an additional 1,820 shares during the period. GAMMA Investing LLC increased its stake in shares of Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after acquiring an additional 3,424 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Nurix Therapeutics by 67.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after acquiring an additional 3,793 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.